FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1282-1283 March 27, 2003 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The discovery of the DNA code touched off an explosion of our knowledge of the molecular basis of human diseases and sparked ideas about treating inherited diseases with genes. Unfortunately, the first widely publicized attempt at gene therapy, in which the -globin gene was injected into a patient with -thalassemia, undertaken 20 years ago, failed because it was not based on an understanding of gene regulation. This ill-conceived experiment led to a public backlash and an unwarranted fear, bordering on hysteria, of recombinant-DNA research and its clinical applications. It soon became clear that identifying a gene sequence and a disease-causing . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Baylor College of Medicine, Houston.

This article has been cited by other articles:

• Tanaka, T., Miyata, T., Inagi, R., Fujita, T., Nangaku, M. (2004). Hypoxia in Renal Disease with Proteinuria and/or Glomerular Hypertension. Am. J. Pathol. 165: 1979-1992 [Abstract] [Full Text]  
• Pantuck, A. J., Zeng, G., Belldegrun, A. S., Figlin, R. A. (2003). Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway. Clin. Cancer Res. 9: 4641-4652 [Abstract] [Full Text]